



23 May 2025

Sydney, Australia

Lead Drug Candidate Renamed to Xolatryp™

Highlights:

- Reflecting its advancing stage of development, Nyrada has renamed lead drug candidate NYR-BI03 to Xolatryp™.
- A trademark has been filed.

Nyrada Inc (ASX:NYR), a drug discovery and development company focused on innovative Transient Receptor Potential Canonical (TRPC) ion channel inhibitors, today provides an update on its lead drug candidate.

Lead Drug Candidate Xolatryp™

Nyrada is advancing the development of its first-in-class small-molecule drug targeting neuroprotection and cardioprotection.

Previously referred to as NYR-BI03, the compound will now be known as Xolatryp™, reflecting its continued progress and demonstrated efficacy in models of ischemic stroke, traumatic brain injury (TBI), and ischemia-reperfusion injury.

A trademark application for the Xolatryp™ name has been filed.

About Xolatryp™

In February 2024, Nyrada announced [preclinical stroke study results](#) showing that NYR-BI03 achieved a statistically significant neuroprotective effect, rescuing 42% of brain tissue in the penumbra region of treated animals.

In October 2024, Nyrada announced the results of a [preclinical coronary heart disease](#) study, which showed that NYR-BI03 provided an 86% cardioprotective effect following myocardial ischemic-reperfusion injury, a leading cause of tissue damage when blood flow is restored to the heart after injury. Further [supporting efficacy data](#) was provided through echocardiography assessment showing significant improvements in heart function and structure following NYR-BI03 treatment

In April 2025, Nyrada announced the results of a [preclinical traumatic brain injury](#) study which showed that NYR-BI03 provided a statistically significant ($p = 0.043$) neuroprotective effect following a penetrating traumatic brain injury. This study was undertaken in collaboration with the [Walter Reed Army Institute of Research](#) and [UNSW Sydney](#).



In May 2025, Nyrada announced the results of a follow up [preclinical coronary heart disease](#) study. This study showed that NYR-BI03 provided 42% cardioprotection when administered continuously for only 3 hours. In addition to protecting the irreplaceable heart tissue, and reducing injury biomarker levels, the incidence of arrhythmia parameters including ventricular fibrillation and ventricular tachycardia, the leading causes of sudden cardiac death, were significantly reduced.

-ENDS-



About Nyrada Inc.

Nyrada Inc. is a biotechnology company focused on the discovery and development of innovative small-molecule therapies, specifically targeting Transient Receptor Potential Canonical (TRPC) ion channels. The company's lead candidate, NYR-BI03, has shown efficacy in both neuroprotection and cardioprotection, is currently undergoing a first-in-human Phase I clinical trial. Nyrada Inc. (ARBN 625 401 818) is incorporated in Delaware, USA, with limited liability for its stockholders.

www.nyrada.com

Authorised by Mr. John Moore, Non-Executive Chair on behalf of the Board.

Investors and Media:

Dimitri Burshtein

T: 02 9498 3390

E: info@nyrada.com

Company Secretary:

David Franks

T: 02 8072 1400

E: David.Franks@automicgroup.com.au

Forward-Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as "aim", "anticipate", "assume", "believe", "continue", "could", "estimate", "expect", "intend", "may", "plan", "predict", "project", "plan", "should", "target", "will" or "would" or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections, and assumptions made by Nyrada about circumstances and events that have not yet taken place. Although Nyrada believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control that could cause the actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statement.